(Jewish Chronicle-UK) Jacob Judah - Teams at the Weizmann Institute for Science in Israel and the Diamond Light Source laboratory in Oxfordshire outlined their current findings and research plans in a discussion hosted by Weizmann UK on Thursday. Weizmann Vice President for Public Affairs and Resource Development Roee Ozir said, "We have probably somewhere between 20 and 30 initiatives of talented and creative scientists who are trying to push their research very quickly and look for remedies as soon as possible." Dr. Nir London, who is leading the team at Weizmann that is searching for a drug candidate, said they are seeking to develop an anti-viral drug which will target protease, one of the 30 proteins that are essential for the activity of the virus. The Weizmann Institute and its international partners are seeking to conduct multiple stages of its research concurrently and thereby shorten the research cycle. Weizmann has pioneered a form of research that is "completely open and shared in real time with the entire scientific community." To find the compounds that are able to inhibit protease, "instead of following up on only a few tens of compounds, we aim to follow up on 500 to a 1,000 compounds in parallel and so drastically shorten the timescale," London said. The team published the data that they had gathered online and issued a "call to arms to medical chemists around the world" inviting them to submit proposals for which compounds might be best placed to bind to the coronavirus. "Within a few days, we got hundreds of proposals from medicinal chemists all around the world....Our premise is that if there is a safe compound which shows efficacy against the virus, humanity needs to know about this fast."
2020-03-31 00:00:00Full ArticleBACK Visit the Daily Alert Archive